Trial Profile
Safety of Romiplostim (Nplate) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Cord blood stem cell transplant rejection; Stem cell engraftment
- Focus Adverse reactions
- 05 Jun 2021 Status changed from active, no longer recruiting to completed.
- 01 Jun 2021 Results assessing safety profile and maximum tolerated dose (MTD) of romiplostim and to investigate whether romiplostim accelerates platelet recovery post-UCBT published in the Transplantation and Cellular Therapy
- 18 Apr 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.